好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Assessing the immediate effect of ground reaction ankle foot orthoses on balance in individuals with inherited neuropathies
Neuromuscular and Clinical Neurophysiology (EMG)
P3 - Poster Session 3 (5:30 PM-6:30 PM)
12-043

The objective of the study is to determine the immediate impact of ground reaction ankle foot orthoses (AFOs) on balance during static standing and during ambulation for individuals with inherited motor or sensory neuropathies.

Inherited neuropathies cause weakness and atrophy of the muscles generally in distal extremities, with or without sensory changes.  These impairments contribute to impaired balance and gait, and increase risk for falls and secondary injuries. Ground reaction AFOs are one type of lower extremity orthosis that can be prescribed to help improve gait. To our knowledge, there are no studies that look at the immediate impact of these AFOs on balance in this population.

Participants were seen in clinic by a physical therapist and orthotist.  Individuals who were clinically appropriate to trial AFOs in clinic were asked to complete the modified Clinical Test of Sensory Interaction and Balance (mCTSIB) and the 4-item Dynamic Gait Index (DGI) with and without AFOs on to assess static and dynamic balance. To minimize the ceiling effect with the DGI, AFOs were not considered an “assistive device” for any of the items.  

To date, there have been 6 participants in this study. The average DGI scores were 7.5/12 without the AFOs on and 10.5/12 with the AFOs on.  Two participants demonstrated improved performance on condition 1 of the mCTSIB, none declined. All six participants demonstrated improved performance on condition 2.  On condition 3, one participant demonstrated improvement with AFOs, while another demonstrated a decline in performance.  For condition 4, one participant demonstrated improved performance with AFOs, while four participants demonstrated a decline with the AFOs.

The findings to date suggest an immediate improvement in dynamic balance during ambulation, with mixed data on static standing balance.  We are currently enrolling for this study and will present updated results.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
Amy Swartz No disclosure on file
Natalie Grant Natalie Grant has nothing to disclose.
Sabrina Paganoni, MD, PhD Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jannsen. Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Paganoni has received personal compensation in the range of $0-$499 for serving as a Consultant for Sola. Dr. Paganoni has received personal compensation in the range of $0-$499 for serving as a Consultant for Frequency Therapeutics. The institution of Dr. Paganoni has received research support from Amylyx. The institution of Dr. Paganoni has received research support from Revalesio. The institution of Dr. Paganoni has received research support from Alector. The institution of Dr. Paganoni has received research support from UCB. The institution of Dr. Paganoni has received research support from Biohaven. The institution of Dr. Paganoni has received research support from Clene. The institution of Dr. Paganoni has received research support from Prilenia. The institution of Dr. Paganoni has received research support from Seelos. The institution of Dr. Paganoni has received research support from Calico. The institution of Dr. Paganoni has received research support from Denali. The institution of Dr. Paganoni has received research support from Anelixis. The institution of Dr. Paganoni has received research support from Cytokinetics.
Reza Seyedsadjadi, MD Dr. Seyedsadjadi has received personal compensation for serving as an employee of American Neurological Association. Dr. Seyedsadjadi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio Therapeutics. Dr. Seyedsadjadi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Seyedsadjadi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Dr. Seyedsadjadi has received research support from Cystinosis Research Foundation.